INTRODUCTION
============

Neck dissection (ND) as a therapeutic or elective intention is one of the most commonly used surgical procedures in the treatment of various head and neck cancers. The surgical technique has been well-standardized and has contributed to improved disease control for patients with head and neck cancers \[[@b1-ceo-2015-00073],[@b2-ceo-2015-00073]\]. However, ND, particularly comprehensive dissection, may be accompanied by postoperative morbidities associated with radical resection of tissue such as hematoma, seroma, chyle fistula, wound infection, and skin flap complications \[[@b3-ceo-2015-00073]\]. To reduce these complications, negative pressure drainage systems are used for complete drainage of fluid collection \[[@b4-ceo-2015-00073]\]. Topical hemostatic agents including fibrin sealant or collagen sealant patches have also been widely used in various fields to reduce overall drainage \[[@b5-ceo-2015-00073]-[@b8-ceo-2015-00073]\]. However, benefits of these local materials is questionable because their mechanism of action depends mainly on mechanical sealing of transected tissue via an induced coagulation process, and they usually cannot cover the whole surgical bed in surgeries of comprehensive extent \[[@b5-ceo-2015-00073]\]. In fact, there are conflicting trial results in terms of the efficacy of sealing agents for reducing postoperative drainage \[[@b9-ceo-2015-00073]-[@b11-ceo-2015-00073]\].

In contrast to the topical hemostatic materials, systemic administration of somatostatin can directly inhibit lymph production and reduce lymph flow into the lymphatic duct by inhibition of endocrine and exocrine secretions of the pancreas, intestine, and gallbladder, as well as by inhibiting nutrient absorption from the intestine and decreasing splanchnic blood flow \[[@b12-ceo-2015-00073]-[@b14-ceo-2015-00073]\]. On the basis of this premise, octreotide, a long-acting somatostatin analog, has been used as a medical treatment option for iatrogenic or congenital lymphorrhea, and has been described in most reports as highly effective with very few adverse effects \[[@b14-ceo-2015-00073]-[@b16-ceo-2015-00073]\]. Considering the theoretical mechanisms and clinical evidences, we hypothesized that octreotide would reduce drainage after ND by reducing overall lymphatic flow in the neck as well as thoracic duct flow, even in cases without chyle fistula. To date, there have been no studies concerning the effect of the routine use of octreotide to reduce drainage after ND. The primary objective of the present study was to determine whether octreotide would provide clinical reductions in postoperative drainage after comprehensive ND. The secondary objective was to evaluate the effect of octreotide on triglyceride (TG) concentrations of drainage, which would suggest a possible effect of octreotide on the nature of the drainage.

MATERIALS AND METHODS
=====================

Study design and patients
-------------------------

This study was designed as a prospective matched case-control study. The Institutional Review Board of Kyungpook National University Hospital approved the study protocol (registration number: 2012-09008), and written informed consent for the study was obtained from all patients.

We confined the extent of ND for eligibility to left-sided comprehensive ND including modified radical ND of level I to V or selective ND of level II to V considering the anatomical location of the major lymphatic duct in the lower neck, which terminates at the angle of the junction of the left internal jugular and subclavian veins \[[@b17-ceo-2015-00073]\].

From May 2012 to January 2014, total 123 patients who underwent comprehensive ND of the lateral compartment of the left neck for the management of head and neck cancer were enrolled in the study. After being provided with sufficient information about the possible benefits and risks of the octreotide administration, each patient selected his or her own study group before the surgery and was enrolled into either an octreotide group (49 patients) or a control group (74 patients). From these, 17 patients from the octreotide group and 17 from the control group who were individually matched by age (±10 years), sex, body mass index (BMI, ±1 kg/m^2^), type of cancer, surgeon, and extent of surgery were finally included in the study.

Exclusion criteria included previous ND, previous radiotherapy or chemotherapy, steroid medication within the past 6 months, anticoagulation medication, uncontrolled hyperlipidemia with preoperative fasting serum TG concentrations \>150 mg/dL, and uncontrolled diabetes mellitus.

Surgical technique
------------------

All NDs were performed by 2 head and neck surgeons (DA and JHS). The harmonic scalpel is routinely used for tissue dissection and hemostasis; however, we utilized a conventional clamp-andtie technique for the dissection of the lower level IV region in concern of the thoracic duct fistula. All ND procedures were performed carefully, particularly around high risk areas for bleeding or chyle fistula. Dissection to identify the major lymphatic duct was not routinely used because the risk of iatrogenic injury to the duct might increase. At the completion of the dissection, all patients were carefully observed for potential chyle leakage. Each patient was placed in the Trendelenburg position, and the wound was observed during prolonged positive pressure ventilation. Routine blind suturing of soft tissue is not performed as long as intraoperative thoracic duct injury is unsuspected. After secure hemostasis, two closed-suction drains were placed and the wounds were closed layer by layer.

Administration of octreotide and management of drains
-----------------------------------------------------

In the octreotide group, octreotide 0.1 mg was administered subcutaneously immediately after surgery and repeated every 8 hours (3 times a day) until postoperative day (POD) 5. All patients in the both groups resumed regular oral diets on the first day after surgery. The amount of fluid from the closed-suction drains was recorded daily at 6 AM and the TG concentration in the drainage fluid was checked daily until POD 5. Biochemical chyle fistula was defined as TG concentration of drainage \>100 mg/dL without any clinical signs or symptoms of chyle fistula such as massive increase of drainage amount, milky drain production, and wound swelling while clinical chyle fistula was defined in the presence of clinical signs or symptoms of chyle fistula combined with TG concentrations of drainage fluid of \>100 mg/dL. In cases of biochemical chyle fistula, only nutritional modification consisting of a medium chain TG diet was used and the TG concentration of the drainage fluid was monitored until it was stable within normal range. In cases of clinical chyle fistula, nutritional modification and pressure dressings were used.

When the total drain output decreased to \<15 mL, the drain was removed. All patients were assessed twice daily, including inspection of wound and color of drainage. Laboratory studies including complete blood count, serum biochemistry, and lipid profile were obtained on POD 1, 3, and 5.

Patients were monitored for possible adverse events of octreotide use on the basis of history and physical examination as well as laboratory studies. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0 (National Cancer Institute, Bethesda, MD, USA). If any grade 3--4 adverse events occurred during the period of octreotide administraion, the patients would be withdrawn from the study and appropriate management for the adverse events would be provided.

Statistical analyses
--------------------

SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. Continuous data were presented as mean±standard deviation and were compared between groups using independent Student *t*-test. Categorical data were compared using chi-square test or Fisher exact test. Statistical significance was defined as *P*\<0.05 and all *P*-values were two-sided throughout.

RESULTS
=======

Patient characteristics
-----------------------

Since this study was designed as a matched case-control study to eliminate major confounding factors, there were no significant differences with respect to age, sex, body weight, BMI, type of cancer, and types of ND ([Table 1](#t1-ceo-2015-00073){ref-type="table"}). The mean number of harvested lymph node was also comparable between the 2 groups (49.4±28.1 vs. 48.7±21.6, *P*=0.706). Although the mean number of positive lymph node was lower in the octreotide group compared to the control group, this difference was not statistically significant (6.3±6.4 vs. 9.4±8.6, *P*=0.238).

Characteristics of postoperative drainage
-----------------------------------------

Postoperative drainage fluid volume, TG concentrations in the drainage fluid, and incidence of chyle fistula are listed in [Table 2](#t2-ceo-2015-00073){ref-type="table"}. Total drainage volume and drainage volume during POD 1--5 were significantly lower in the octreotide group compared to the control group (540.9±308.5 mL vs. 807.9±342.4 mL, *P*=0.025; 461.1±245.7 mL vs. 676.4±262.6 mL, *P*=0.02, respectively). The duration of drain placement was also significantly shorter in the octreotide group compared to the control group (6.3±1.5 days vs. 9.4±4.1 days, *P*=0.013).

Biochemical analysis of the drainage fluid showed that the mean TG concentrations during POD 1--5 was lower in the octreotide group than in the control group and this difference was statistically significant (43.1±18.3 mg/dL vs. 88.8±64.2 mg/dL, *P*=0.034). In the octreotide group, only biochemical chyle fistula was found in 1 patient (5.9%). In the control group, biochemical and clinical chyle fistulae were found in 3 patients (17.6%) and 1 patient (5.9%), respectively. These differences were not statistically significant (*P*=0.335).

Adverse events possibly related to octreotide use
-------------------------------------------------

[Table 3](#t3-ceo-2015-00073){ref-type="table"} lists the incidence of adverse events that were possibly related to octreotide use. There were no significant differences between the two groups in any types of adverse events. Hyponatremia (serum sodium concentration\<130 mmol/L) and hypoglycemia (fasting serum glucose concentration\<55 mg/dL) were the most common adverse events, occurring in 4 patients (23.5%) of the octreotide group. However, these adverse events were also found in 6 (35.3%) and 3 patients (17.6%) of the control group, respectively. All adverse events were classified as grade 1 according to the CTCAE ver. 4.0 and all patients of the octreotide group completed the full course of intended postoperative administration of octreotide.

DISCUSSION
==========

The primary aim of the present study was to investigate whether postoperative administration of octreotide would reduce postoperative drainage volume. We found that the postoperative fluid drainage volume reduced significantly in the octreotide group. Furthermore, the reduction in postoperative fluid drainage contributes to drain removal approximately 3 days earlier than that in the control group. Although 4 out of the 17 patients in the octreotide group showed a small reincrease in drainage volume after stopping octreotide injection, this increase was transient and the readministration of octreotide or any other forms of management was not required. We assumed that this result was associated with the effect of octreotide on the lymphatic system, i.e., octreotide reduces lymphatic production and flow. In the context of chyle fistula, the efficacy of somatostatin may be a result of its ability to reduce gastric, pancreatic, and intestinal secretion, to inhibit the motor activity of the intestine, ant to slow the process of intestinal absorption, reduce splanchnic blood flow, and decrease hepatic venous pressure \[[@b13-ceo-2015-00073],[@b16-ceo-2015-00073]\]. In fact, a prospective study in dogs has demonstrated a threefold decrease in thoracic duct flow and decreased ratio of TG after administration of octreotide \[[@b18-ceo-2015-00073]\]. Similarly, in the present study, the TG concentrations in the postoperative drainage fluid were consistently lower in the octreotide group than in the control group throughout the postoperative period. These results suggest that both the lymph flow and TG concentrations in the major lymphatic channels were attenuated by octreotide injection, even though our study population did not initially included patients with chyle fistula. Furthermore, there was a trend toward a lower incidence of chyle fistula (biochemical or clinical) in the octreotide group. This finding also supports the hypothesized effect of octreotide on the lymphatic system and corresponds with the results of previous studies \[[@b12-ceo-2015-00073],[@b15-ceo-2015-00073],[@b16-ceo-2015-00073]\].

Interestingly, the overall incidence of chyle fistula in the present study was 14.7% (5 of 34), which was considerably higher than that expected or described in the literature so far (reported range, 1% to 5.8%) \[[@b13-ceo-2015-00073],[@b14-ceo-2015-00073],[@b19-ceo-2015-00073]\]. This may have been due to close prospective monitoring of our patients for potential chyle leakage. Although there have been no obvious signs or symptoms of chyle fistula to facilitate diagnosis during the postoperative period, routine biochemical assay of the drainage fluid may have affected the rate of clinical diagnosis. In a study by Roh et al. \[[@b17-ceo-2015-00073]\] regarding the prospective identification of chyle fistula in patients undergoing lateral ND for metastatic thyroid cancer, postoperative chyle fistula was observed in 8.3% patients, which was also higher incidence than that reported previously. Therefore, chyle fistula may be more frequent after ND than previously experienced, although only a minority of these patients are identified clinically and require active management. In fact, the incidence of clinical chyle fistula was only 2.9% (1 of 34) in our study, which is comparable to the previous studies.

As a preliminary study, the present study has some limitations that could be addressed by further investigation. First, the cost-effectiveness and impact on quality of life due to repeated octreotide administration were not evaluated in the present study. We assume that earlier patient discharge would result from reduced fluid drainage volume and could contribute to reducing overall medical costs and an earlier return to routine social life. However, these benefits should be weighed against the additional costs and discomfort associated with multiple octreotide injections. Second, considering that the postoperative fluid collection is a consequence of surgical disruption of lymphatics and capillaries with ensuing leakage of fluid into the dead space created by surgical dissection \[[@b20-ceo-2015-00073]\], combining use of octreotide to reduce systemic lymphatic flow and a topical hemostatic agent to reduce the volume of dead space and seal leaking capillaries and lymphatic channels would theoretically be more powerful methods. To verify this, prospective randomized controlled trials including control group, a topical hemostatic agent group, a systemic octreotide group, and a topical hemostatic agent + systemic octreotide group should be performed.

In conclusion, this prospective matched case-control study has shown that postoperative octreotide injection in patients undergoing left-sided comprehensive ND reduces postoperative drainage volume and TG concentration in drainage fluid, resulting in earlier removal the drain without any adverse events. Further studies with larger patient populations are warranted to confirm these results and to evaluate the clinical benefits for patients.
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###### 

Characteristics of 34 patients enrolled into the study

  Characteristic                                  Octreotide group (n=17)   Control group (n=17)   *P*-value
  ----------------------------------------------- ------------------------- ---------------------- -----------
  Age (yr)                                        63.1±12.3                 59.0±18.0              0.442
  Sex (male:female)                               10:7                      10:7                   \-
  Body weight (kg)                                57.4 ±9.3                 60.5±10.2              0.359
  Body mass index (kg/m^2^)                       22.7±3.0                  22.8±2.8               0.970
  Disease                                                                                          
   Thyroid cancer                                 11                        11                     \-
   Laryngohypopharyngeal cancer                   2                         2                      \-
   Oral cavity-oropharygneal cancer               2                         2                      \-
   Metastatic carcinoma of unknown primary site   2                         2                      \-
  Type of neck dissection                                                                          
   SND (level II-V)                               11                        11                     \-
   mRND (level I-V)                               6                         6                      \-
  No. of harvested lymph nodes                    49.4±28.1                 48.7±21.6              0.706
  No. of positive lymph nodes                     6.3±6.4                   9.4±8.6                0.238
                                                                                                   

Values are presented as mean±SD or number.

SND, selective neck dissection; mRND, modified radical neck dissection.

###### 

Characteristics of postoperative fluid drainage in control and octreotide treated patients.

  Characteristic                                      Octreotide group (n=17)   Control group (n=17)   *P*-value
  --------------------------------------------------- ------------------------- ---------------------- --------------------------------------------------------
  Total drainage volume (mL)                          540.9±308.5               807.9±342.4            0.025^[\*](#tfn5-ceo-2015-00073){ref-type="table-fn"}^
  Drainage volume during POD 1-5 (mL)                 461.1±245.7               676.4±262.6            0.021^[\*](#tfn5-ceo-2015-00073){ref-type="table-fn"}^
  Duration of drain placement (day)                   6.3±1.5                   9.4±4.2                0.013^[\*](#tfn5-ceo-2015-00073){ref-type="table-fn"}^
  Triglyceride concentration during POD 1-5 (mg/dL)   43.1±8.3                  88.8±64.2              0.034^[\*](#tfn5-ceo-2015-00073){ref-type="table-fn"}^
  Incidence of overall chyle fistula                  1 (5.9)                   4 (23.5)               0.335
   Biochemical                                        1 (5.9)                   3 (17.6)               0.601
   Clinical                                           0                         1 (5.9)                \>0.999

Values are presented as mean±SD or number (%).

POD, postoperative day.

*P*\<0.05, statistically significant differences between the groups.

###### 

Adverse events possibly related to octreotide use

  Adverse event            Octreotide group (n=17)   Control group (n =17)   *P*-value
  ------------------------ ------------------------- ----------------------- -----------
  Nausea                   3 (17.6)                  2 (11.8)                \>0.999
  Vomiting                 2 (11.8)                  1 (5.9)                 \>0.999
  Abdominal pain           1 (5.9)                   1 (5.9)                 \>0.999
  Diarrhea                 0                         1 (5.9)                 \>0.999
  Hypoglycemia             4 (23.5)                  3 (17.6)                \>0.999
  Hyponatremia             4 (23.5)                  6 (35.3)                0.708
  Liver enzyme elevation   0                         0                       \-

Values are presented as number (%).
